A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients

NCT00001504 ·Status: COMPLETED ·Phase: PHASE1

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT01124695 ·Status: COMPLETED ·Phase: PHASE2

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322 ·Status: COMPLETED ·Phase: PHASE2

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

NCT01357772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

NCT00002581 ·Status: COMPLETED ·Phase: PHASE3

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

NCT00253539 ·Status: COMPLETED ·Phase: PHASE2

Fenretinide in Healthy Young Women at Genetic and Familial Risk

NCT01479192 ·Status: TERMINATED ·Phase: PHASE3

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

NCT01196936 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

NCT00569543 ·Status: COMPLETED

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956 ·Status: TERMINATED ·Phase: PHASE2

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

NCT05941520 ·Status: RECRUITING ·Phase: PHASE2

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

NCT03351062 ·Status: RECRUITING ·Phase: PHASE3

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

NCT02936206 ·Status: TERMINATED ·Phase: PHASE1

Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients

NCT03931928 ·Status: COMPLETED ·Phase: PHASE2

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

NCT00830973 ·Status: COMPLETED

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159 ·Status: COMPLETED ·Phase: PHASE2

Therapeutic Dose Monitoring (TDM) of Tamoxifen

NCT05133674 ·Status: UNKNOWN ·Phase: PHASE2

Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer

NCT00005605 ·Status: COMPLETED

Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer

NCT00967824 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.

NCT00287534 ·Status: COMPLETED ·Phase: PHASE2

Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer

NCT00086749 ·Status: COMPLETED

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690 ·Status: COMPLETED ·Phase: PHASE3

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

NCT00031720 ·Status: COMPLETED ·Phase: PHASE2

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

NCT00952731 ·Status: COMPLETED ·Phase: PHASE2

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00899197 ·Status: TERMINATED